

FGFR1, c-Kit, RET, and B-Raf.

 Phone:
 888-558-5227

 651-644-8424

 Fax:
 888-558-7329

 Email:
 getinfo@lktlabs.com

 Web:
 lktlabs.com

Product Information

Product ID	R1626			
	1019206-88-2			
Chemical Name Synonym	BAY73-4506	ин ин)=0 . н₂о	
Formula	$C_{21}H_{15}CIF_4N_4O_3 \cdot H_2O$		F Cl	
Formula Wt.	500.83			
Melting Point		Bulk quanitites available upon request		
Purity		Product ID	Size	
Solubility	insoluble in water between pH1 and 13, slightly soluble in methanol; ethanol and sparingly soluble in acetone	R1626	1 mg	
		R1626	5 mg	
		R1626	25 mg	
Store Temp	-20°C	R1626	100 mg	
Ship Temp	Ambient			
Description	Regorafenib is an orally bioavailable multikinase inhibitor. This compound is clinically used in the treatment of metastatic colorectal cancer and non-responsive gastrointestinal stromal tumors. Regorafenib displays anticancer chemotherapeutic and anti- angiogenic properties, selective primarily for VEGFR2 but also displaying inhibitory activity against TIE2, VEGFR1/3, PDGFR-β,			

References Abou-Elkacem L, Arns S, Brix G, et al. Regorafenib inhibits growth, angiogenesis, and metastasis in a highly aggressive, orthotopic colon cancer model. Mol Cancer Ther. 2013 Jul;12(7):1322-31. PMID: 23619301.

Wilhelm SM, Dumas J, Adnane L, et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer. 2011 Jul 1;129(1):245-55. PMID: 21170960.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.